Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

benzinga.com/news/health-care/25/10/48233018/eli-lillys-oral-weight-loss-drug-shows-superiority-over-two-approved-drugs

Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.
LLY is gathering positive momentum. See what is happening here.
ACHIEVE-2, the second head-to-head trial, evaluated…

This story appeared on benzinga.com, 2025-10-15 17:24:50.
The Entire Business World on a Single Page. Free to Use →